Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission compared...
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old...
Recommendation supported by findings from quadruplet therapy PERSEUS study with daratumumab subcutaneous (SC) formulation in the frontline setting Findings showed...
Experienced Life Sciences Executive Brings Strategic Expertise to Support Traws’ Further Transformation and Growth Director James J Marino Also to...
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE20 SEPTEMBER 2024 at 9.30...
Kineta will be trading under the symbol “KANT” on OTC Pink Kineta will continue to pursue strategic alternatives as previously...
NEW YORK, Sept. 19, 2024 /PRNewswire/ -- The Dana-Farber Cancer Institute, a world leader in cancer treatment and research, chose Clinical.ly's...
CRANBURY, N.J., Sept. 19, 2024 /PRNewswire/ -- The Academy of Oncology Nurse & Patient Navigators (AONN+) is pleased to announce...
TORONTO, ON / ACCESSWIRE / September 19, 2024 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
CHICAGO, IL / ACCESSWIRE / September 19, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...
Published data shows that chemotherapy delivered via TAMP with prior chemoradiation in Locally Advanced Pancreatic Cancer observed an Overall Survival...
Helsinn Group appoints Riccardo Carbucicchio to the Board of Directors Lugano, Switzerland – September 19, 2024 – Helsinn Group (“Helsinn”), a...
The new version 5.0 of the AI model EDEN™ features a novel toxin antigen predictor, is trained on an expanded...
Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort Combination...
New patent expected to expire in 2030 Tosymra® (sumatriptan nasal spray) 10mg is indicated and marketed for the acute treatment...
–Achilles to discontinue development of TIL-based cNeT therapy– –Cash position of $95.1 million as of June 30, 2024– –BofA Securities...
Garching / Munich, September 19, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced...
Initial funding of USD 29 million to support development of Basilea’s clinical stage first-in-class antifungals, fosmanogepix and BAL2062Multi-year Other Transaction...
London (UK), September 19 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical...